Research reportThe involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model

Chronic dopamine (DA) replacement therapy with l-3,4-dihydroxyphenylalanine (l-DOPA) in Parkinson's disease (PD) often leads to abnormal involuntary movements (AIMs) known as l-DOPA-induced dyskinesia (LID), mediated by DA receptors. However, mechanisms underlying LID occurrence are still unclear. Regulator of G-protein signaling RGS9, a member of the RGS family of GTPase accelerating proteins, is expressed specifically in the striatum, has been reported participated in LID. l-DOPA-induced AIMs can be modeled in rats with 6-hydroxydopamine (6-OHDA) lesions by chronic injection of l-DOPA. Herein, we compared the rotational responses and AIMs in 6-OHDA lesioned rats with l-DOPA/benserazide (10/2.5 mg/kg, once per day, i.p.) administration for 14 days whereas control animals received injections of saline. Furthermore, whether sub-chronic l-DOPA treatment impact RGS9 mRNA or protein expression in 6-OHDA lesion rats were also evaluated. As results shown, rotational behavior was not increased significantly, while an obvious AIMs were observed in rats with l-DOPA/benserazide (10/2.5 mg/kg, i.p.) administration sub-chronically. In addition, expressions of RGS9 protein or mRNA analyzed by Western blot or real-time PCR with striatal extracts increased significantly after l-DOPA/benserazide. These data demonstrate that RGS9 expression can be modulated by sub-chronic l-DOPA/benserazide administration and increased RGS9 expression in striatum may be one of the reasons for the side effects such as dyskinesia induced by l-DOPA therapy.

► Whether l-DOPA sub-chronic treatment altered RGS9 expressions in 6-OHDA lesion rats were evaluated. ► l-DOPA/benserazide (10/2.5 mg/kg, i.p.) given subchronically increased expressions of RGS9 protein or mRNA. ► We deduced that increased RGS9 expression in striatum maybe one of reasons for the side effects induced by l-DOPA therapy.